When Roger first came home, he was terrified of everything. The senior dog, who has dwarfism and a body as unique as his story, arrived anxious, reactive, and unsure if he could trust anyone. Even ...

If David Attenborough has taught us anything, it is that animals make life worth living. Whether they are furry, feathered, ...

One of the most extreme animal survival stories on the planet has just revealed a secret no one expected to find.

Several dog breeds are currently banned in the UK, with ownership of these animals not only being against the law, but also ...

From the moment Ozzie learned how to run, he decided the giant dogs on the farm were officially his responsibility. The tiny horse races after them constantly, trying to prove he’s the fastest animal ...

Julie Wyman explores her place in the community of little people in the new PBS documentary 'The Tallest Dwarf' PBS Filmmaker Julie Wyman, who says she inherited “short arms and legs, and a long torso ...

Despite not knowing she had dwarfism until later in life, Julie Wyman always sensed there was something “different” about her. “I always had this experience of not fitting in physically,” Wyman, 56, ...

Their shows caused mayhem. Now Tamm Reynolds – AKA Midgitte Bardot – is really going for the jugular, hitting back at prejudice with a wild new act Most performers want attention when they’re on stage ...

ARVADA, Colo. — A 6-year-old Arvada boy diagnosed with achondroplasia, the most common form of dwarfism, is thriving in his kindergarten classroom — not just because of the care he receives at ...

Ascendis Pharma has secured accelerated approval for its navepegritide (Yuviwel) to accelerate the growth of children 2 years of age and older with achondroplasia, a common form of dwarfism.

Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's (A71.F), opens new tab once-weekly therapy for children with a rare genetic disorder that causes dwarfism, ...

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children. The FDA granted infigratinib, which was ...